2. Heidelberg Liver Tumor Symposium

Latest findings in therapy of cholangiocellular carcinoma

At the 2. Heidelberg Liver Tumor Symposium, which took place at the University Hospital Heidelberg on March, 12th, 2016 experts of the LCCH discussed new diagnostic approaches, therapies, and study concepts together with local liver tumor clinicians.

This time the focus of our discussion was on tumors of the intra- and extra hepatic bile ducts and the gall bladder, as the occurrence of these tumors increases while prognosis is still poor. Early detection of these tumors also remains a so far unsolved problem.

Invited speaker Prof. Dr. med. A. Vogel of the Hannover Medical School referred about latest approaches and current scientific findings concerning the formation and growth of bile duct and gall bladder tumors. Therapy options are changing and even for this poorly treatable tumor entity newly identified molecular target structures provide opportunities to test new targeted drugs in clinical studies. Immunotherapy – also a focus in the frame of NCT Heidelberg’s tumor therapy - shows first promising results and the future can be seen in the individualized therapy on the basis of molecular and morphological marker.

Best interdisciplinary cooperation

A unique feature of the patient care is the central structure of the Liver Cancer Center Heidelberg guaranteeing the best interdisciplinary cooperation and, thus, the best possible therapy for the patient.